CoChat
Sign Up
Cited by 218Antifungal resistance and susceptibilityOcular Infections and TreatmentsInfective Endocarditis Diagnosis and Management

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Ocular Manifestations of Candidemia

Open access
Oude Lashof, A. M. L., Rothova, A., Sobel, J. D., Ruhnke, M., Pappas, P. G., Viscoli, C., Schlamm, H. T., Oborska, I. T., Rex, J. H., Kullberg, B. J.·2011·Clinical Infectious Diseases
DOI 10.1093/cid/cir355
Open this paper in CoChat — free account

Abstract

BACKGROUND: Ocular candidiasis is a major complication of candidemia. The incidence, risk factors, and outcome of eye involvement during candidemia are largely unknown. We prospectively studied the ocular manifestations of candidemia in a large, worldwide, randomized multicenter trial that compared voriconazole with amphotericin B followed by fluconazole for the treatment of candidemia. METHODS: Nonneutropenic patients with blood cultures positive for Candida species were assigned treatment with voriconazole or with amphotericin B followed by fluconazole in a randomized 2:1 ratio. Dilated fundoscopy was performed in each patient at baseline, on day 7, at 2 and 6 weeks after the end of treatment (EOT), and, if clinically indicated, at 12 weeks after EOT. RESULTS: Of 370 patients, 49 had findings consistent with the diagnosis of ocular candidiasis at baseline, and an additional 11 patients developed abnormalities during treatment, totaling 60 patients with eye involvement (16%). Of these patients, probable Candida eye infection was diagnosed in 40 patients (6 with endophthalmitis, 34 with chorioretinitis), and possible Candida eye infection in 20 (all with chorioretinitis). The duration of candidemia was significantly longer in patients with ocular candidiasis (median, 4 days; range, 1-18 days) compared with patients without ocular involvement (median, 3 days; range 1-26 days; log rank, P = .026). Therapy with either voriconazole (44 cases) or amphotericin B followed by fluconazole (16 cases) was successful in 65% of patients; outcome was not evaluable in 32% and was unfavorable in 3%. CONCLUSIONS: Ocular involvement occurred in 16% of patients with candidemia; however, endophthalmitis was uncommon (1.6%). Treatment with either voriconazole or amphotericin B followed by fluconazole was successful for ocular candidiasis in most cases with follow-up.

Overview

Integrity signals

Registry

Crossref · 10.1093/cid/cir355

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Flagged first, then by citations

Show all 29 references

Research works printed but not linked: 1

  1. Rodr guez-Adri n, 2003, Medicine, 82, 187

Cited by

Sorted by citations

Items 201–218 of 218

Related

See all

Metadata

Authors
Oude Lashof, A. M. L., Rothova, A., Sobel, J. D., Ruhnke, M., Pappas, P. G., Viscoli, C., Schlamm, H. T., Oborska, I. T., Rex, J. H., & Kullberg, B. J.
Affiliations
  • Wayne State University (US)
  • Humboldt-Universität zu Berlin (DE)
  • University of Alabama at Birmingham (US)
  • University of Genoa (IT)
  • Pfizer (United States) (US)
  • The University of Texas Health Science Center at Houston (US)
  • Radboud University Nijmegen (NL)
ORCID
Venue
Clinical Infectious Diseases
Publisher
Oxford University Press (OUP)
Published
2011-07-15
Volume
53
Issue
3
Pages
262-268
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
DOI
10.1093/cid/cir355
OpenAlex
W2119470586
Cited by
218
References
29
Citations by year
2026: 7 · 2025: 14 · 2024: 10 · 2023: 16 · 2022: 18 · 2021: 20 · 2020: 15 · 2019: 19 · 2018: 17 · 2017: 15 · 2016: 16 · 2015: 12 · 2014: 16 · 2013: 10 · 2012: 12
FWCI
8.41
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, other-oa)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
Keywords
ocular candidiasis, candidemia, endophthalmitis, chorioretinitis, Candida, voriconazole, amphotericin B, fluconazole, antifungal therapy, non-neutropenic patients, treatment outcomes
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Amphotericin B, Antifungal Agents, Candida, Female, Humans, Male, Middle Aged, Endophthalmitis, Prospective Studies, Pyrimidines, Risk Factors, Triazoles, Fluconazole, Eye Infections, Fungal, Incidence, Young Adult, Candidemia, Voriconazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review